Die Onkologie pp 1181-1201 | Cite as

Nierenzellkarzinom

  • W. E. Aulitzky
  • J. Beck
  • C. Huber

Zusammenfassung

2–3% aller malignen Erkrankungen gehen von der Niere aus (Dayal u. Wilkinson 1989; Tavani u. La Vecchia 1997). In Deutschland wurden 1993 5544 Todesfälle durch maligne Nierentumoren registriert. Damit verursacht das Nierenzellkarzinom in Deutschland ca. 5% aller krebsbedingten Todesfälle und zählt eher zu den seltenen Tumorerkrankungen (Hoelzel et al.1996). Die Inzidenz ist in den letzten Jahrzehnten leicht steigend (Katz et al.1994; Wunderlich et al.1998). Sie variiert erheblich zwischen unterschiedlichen geographischen Regionen um den Faktor 10–20. Männer sind häufiger betroffen als Frauen (Hoelzel et al.1996) und die Erkrankung tritt vorwiegend im höheren Lebensalter mit einem Inzidenzgipfel zwischen 50 und 70 Jahren auf. Es sind aber auch Fälle im Kindesalter beschrieben worden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Akhtar M, Al-Sohaibani MO, Haleem A (1996) Flow cytometric analysis of chromophobe cell carcinoma of the kidney.) Urol Path 4: 15–23Google Scholar
  2. Akhtar M,Tulbah A, Kardar AH, Ali MA (1997) Sarcomatoid renal cell carcinoma:the chromophobe connection.Am J Surg Pathol 21: 1188–1195Google Scholar
  3. Al-Saleem T,Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer Si et al. (1998) Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83: 2208–2216PubMedGoogle Scholar
  4. Amato RJ (2000) Chemotherapy for renal cell carcinoma. Seminars in Oncology 27: 117–186Google Scholar
  5. Amendola MA, Bree RL, Pollack HM, Francis IR, Glazer GM, Jafri SZ et al. (1988) Small renal cell carcinomas:resolving a diagnostic dilemma. Radiology 166: 637–641PubMedGoogle Scholar
  6. Amendola MA (1989) Comparison of MR imaging and CT in the evaluation of renal masses.Crit Rev Diagn Imaging 29: 117–150Google Scholar
  7. Amendola MA, King LR, Pollack HM, Gefter W, Kressel HY, Wein Ai (1990) Staging of renal carcinoma using magnetic resonance imaging at 1.5 Tesla. Cancer 66: 40–44PubMedGoogle Scholar
  8. Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A, Menon M (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 Gases. Am J Surg Pathol 26: 281–291PubMedGoogle Scholar
  9. Anonymous (1999) Interferon-alpha and survival in metastatic renal carcinoma:early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14–17Google Scholar
  10. Aso Y, Homma Y (1992) A survey on incidental renal cell carcinoma in Japan.) Urol 147: 340–343Google Scholar
  11. Atzpodien J, Kirchner H, Francke A, Wandt T, Probst M, Duensing S et al. (1997) Results of a randomized clinical trial comparing s.c. interleukin 2, s.c. interferon alpha 2a, and i.v. bolus 5 fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma. Proc ASCO 16: 326a [Abstract]Google Scholar
  12. Atzpodien J, Lopez Hanninen E, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U et al. (1995) Multiinstitutional home-therapy trial of recombinant human interleukin- 2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.J Clin Oncol 13: 497–501Google Scholar
  13. Atzpodien J, Kirchner H, Illiger FU et al. (2001) IL-2 in combination with IFN alpha and 5-FU versus tamoxifen in metastatic renal Gel carcinoma: long term results of a controlled randomized clinical trial. Br J Cancer 85: 1130–1136PubMedGoogle Scholar
  14. Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M (2002) Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95: 1045–1050PubMedGoogle Scholar
  15. Aulitzky W, Gast! G, Aulitzky WE, Herold M, Kemmler J, Mull B et al. (1989) Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 7: 1875–1884PubMedGoogle Scholar
  16. Aulitzky WE, Lerche),Thews A, Luttichau I, Jacobi N, Herold M, et al. (1994) Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden. Eur J Cancer 30A: 940–945Google Scholar
  17. Binkovitz LA, Johnson CD, Stephens DH (1990) Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. Am J Roentgenol 155: 501–505Google Scholar
  18. Birnbaum BA, Bosniak MA, Megibow Ai, Lubat E, Gordon RB (1990) Obser- vations on the growth of renal neoplasms. Radiology 176: 695–701Google Scholar
  19. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP (1996) Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 149: 1201–1208Google Scholar
  20. Blom JH, Schroder FH, Hammond B, Sylvester R (1992) Radical nephrectomy with and without lymph node dissection: preliminary results of EORTC Protocol 30881. The EORTC Genitourinary Group. Prog Clin Biol Res 378: 161–167Google Scholar
  21. Blom JH (1998) Surgery or renal cancer–is lymphadenectomy useful? Acta Urol Belg 66: 37–40PubMedGoogle Scholar
  22. Bodmer D 1998 ) An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a (2;3)(g5;g21) translocation. M J Hum Genet 62: 1475–1483Google Scholar
  23. Bosniak MA (1995) Observation of small incidentally detected renal masses. Semin Urol Oncol 13: 267–272PubMedGoogle Scholar
  24. Bostanci A, Vogel G (2002) Research misconduct. German inquiry finds flaws, not fraud. Science 298: 1531–1533Google Scholar
  25. Brauch H, Pomer S, Hieronymus T, Schadt T, Lohrke H, Komitowski D (1994) Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p,5q, and 17p. World J Urol 12: 162–168PubMedGoogle Scholar
  26. Brownson RC (1988) A case-control study of renal cell carcinoma in relation to occupation, smoking, and alcohol consumption. Arch Environ Health 43: 238–241PubMedGoogle Scholar
  27. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma:the role of interleukin-2. Cancer 80: 1198–1220PubMedGoogle Scholar
  28. Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR (1995) Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 45:34–40; discussion 40–41Google Scholar
  29. Canobbio L, Boccardo F, Guarneri D, Calabria C, Decensi A, Curotto A, et al. (1991) Phase II study of navelbine in advanced renal cell carcinoma (letter). Eur J Cancer 27: 804–805PubMedGoogle Scholar
  30. Chen F, Kishida T,Yao M, Hustad T, Glavac D, Dean M, et al. (1995) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5: 66–75PubMedGoogle Scholar
  31. Cherukuri SV, Johenning PW, Ram MD (1977) Systemic effects of hyperneph roma. Urology 10: 93–97PubMedGoogle Scholar
  32. Childs R,Chernoff A, Contention N et al. (2000) Regression of metastatic renal cell carcinoma after non-myeloablative allogeneic peripheral stem cell transplantation. NEJM 343: 750–754PubMedGoogle Scholar
  33. Choyke PL, Filling-Katz MR, ShawkerTH,Gorin MB,Travis WD, Chang R et al. (1990) von Hippel-Lindau disease: radiologic screening for visceral manifestations. Radiology 174: 815–820Google Scholar
  34. Choyke PL, Glenn GM, Walther MM, Zbar B, Weiss GH, Alexander RB et al. (1992) The natural history of renal lesions in von Hippel-Lindau disease:a serial CT study in 28 patients.Am J Roentgenol 159: 1229–1234Google Scholar
  35. Choyke PL, Glenn GM,Walther MM, Patronas NJ, Linehan WM,Zbar B (1995) von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 194: 629–642Google Scholar
  36. Choyke PL, Glenn GM, Wagner JP, Lubensky IA, Thakore K, Zbar B et al. (1997a) Epididymal cystadenomas in von Hippel-Lindau disease. Urology 49: 926–931PubMedGoogle Scholar
  37. Choyke PL, Walther MM, Glenn GM, Wagner JR,Venzon DJ, Lubensky IA et al. (1997b) Imaging features of hereditary papillary renal cancers. J Comput Assist Tomog r 21: 737–741Google Scholar
  38. Christensen P, Madsen MR, Jensen OM (1983) Latency of thorotrast-induced renal tumours. Survey of the literature and a case report.Scand J Urol Nephrol 17: 127–130Google Scholar
  39. Cockman ME, Masson N, Mole DR et al. (2000) Hypoxia inducible factor alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor product.) Biol Chem 275: 25733–25741Google Scholar
  40. Conaway JW, Kamura T, Conaway RC (1998) The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein. Biochim Biophys Acta 1377: M49–54PubMedGoogle Scholar
  41. Consortium TT (1997) Identification of the TSC-1 gene on chromosome 9q34. Science 227: 805–808Google Scholar
  42. Cornish D, Pont A, Minor D,Coombs JL, Bennington J (1984) Metastatic islet cell tumor in von Hippel-Lindau disease.Am J Med 77: 147–150Google Scholar
  43. Couillard DR,deVere White RW (1993) Surgery of renal cell carcinoma. Urol Clin North Am 20: 263–275PubMedGoogle Scholar
  44. Cozzoli A, Milano S, Cancarini G, Zanotelli T, Cosciani Cunico S (1995) Surgery of lung metastases in renal cell carcinoma. Br J Urol 75: 445–447PubMedGoogle Scholar
  45. Crivellari D,Tumolo S, Frustaci S, Galligioni E, Figoli F, Lo Re G et al. (1987) Phase II study of five-day continuous infusion of vinblastine in patients with metastatic renal-cell carcinoma. Am J Clin Oncol 10: 231233Google Scholar
  46. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F et al. (1994)Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3: 1303–1308Google Scholar
  47. da Silva JL, Lacombe C, Bruneval P,Casadevall N, Leporrier M,Camilleri JP et al. (1990)Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 75: 577–582Google Scholar
  48. Dawson NA, Barr CF, Alving BM (1985) Acquired dysfibrinogenemia. Para- neoplastic syndrome in renal cell carcinoma. Am J Med 78: 682–686Google Scholar
  49. Dayal HH,Wilkinson GS (1989) Epidemiology of renal cell cancer.Semin Urol 7: 139–143Google Scholar
  50. De Mulder PH, Oosterhof G, Bouffioux C, Van Oosterom AT, Vermeylen K, Sylvester R (1995) EORTC (30885) randomised phase Ill study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer 71: 371–375Google Scholar
  51. De Mulder PH,Weissbach L,Jakse G, Osieka R, Blatter1(1996) Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37: 491–495Google Scholar
  52. Decker Hi, Neumann HP,WalterTA, Sandberg AA (1988) 3p involvement in a renal cell carcinoma in von Hippel-Lindau syndrome. Region of tumor breakpoint clustering on 3p? Cancer Genet Cytogenet 33: 59–65Google Scholar
  53. Decker HJ, Gemmill RM, Neumann HP, Walter TA, Sandberg AA (1989) Loss of heterozygosity on 3p in a renal cell carcinoma in von Hippel-Lindau syndrome. Cancer Genet Cytogenet 39: 289–293PubMedGoogle Scholar
  54. Decker HJ, Klauck SM, Lawrence JB, McNeil J, Smith D, Gemmill RM et al. (1994) Cytogenetic and fluorescence in situ hybridization studies on sporadic and hereditary tumors associated with von Hippel-Lindau syndrome ( VHL ). Cancer Genet Cytogenet 77: 1–13Google Scholar
  55. Decker HJ, Weidt EJ, BriegerJ (1997) The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.Cancer Genet Cytogenet 93: 74–83Google Scholar
  56. Delahunt B, Eble JN (1997) Papillary renal cell carcinoma:a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10: 537–544PubMedGoogle Scholar
  57. Dexeus FH, Logothetis CJ, Sella A,Amato R, Kilbourn R, Ogden S et al. (1991) Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma.J Urol 146: 709–713Google Scholar
  58. Ditonno P,Traficante A, Battaglia M, Grossi FS, Selvaggi FP (1992) Role of lymphadenectomy in renal cell carcinoma. Prog Clin Biol Res 378: 169–74: 169–174Google Scholar
  59. Dunn MD, Portis A, Shalhav AL et al. (2000) Laparoscopic versus open radical mephrectomy: a 9 years experience.) Urol 164: 1153Google Scholar
  60. Einzig AI,Gorowski E,SasloffJ,Wiernik PH (1991) Phase II trial oftaxol in patients with metastatic renal cell carcinoma. Cancer Invest 9: 133–136PubMedGoogle Scholar
  61. Engelmann U, Schaub T, Schweden F, Jacobi GH,Thuroff JW (1984) Digital subtraction angiography in staging renal cell carcinoma:comparison with computerized tomography and histopathology. J Urol 132: 1093–1096Google Scholar
  62. Enterline PE (1993) Review of new evidence regarding the relationship of gasoline exposure to kidney cancer and leukemia.Environ Health Perspect 101 [Suppl 61: 101–103Google Scholar
  63. Epstein AC,Gleadle JM, McNeill LA et al. (2001) C.elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43–54PubMedGoogle Scholar
  64. European Consortium on Tuberous Sclerosis (1993) Identification of the tuberous sclerosis gene on chromosome 16. Cell 75: 1305–1315Google Scholar
  65. Filling-Katz MR, Choyke PL,Oldfield E, Charnas L, Patronas NJ, Glenn GM et al. (1991) Central nervous system involvement in von Hippel-Lindau disease. Neurology 41: 41–46PubMedGoogle Scholar
  66. Finney R (1973) The value of radiotherapy in the treatment of hypernephroma–a clinical trial. Br J Urol 45: 258–269PubMedGoogle Scholar
  67. Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F et aí. (1998) Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours.Oncogene 17: 733–739Google Scholar
  68. Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N EngI J Med 345: 1655–1659Google Scholar
  69. Fossa SD, Martinelli G, Otto U, Schneider G, Wander H, Oberling F et al. (1992) Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase Ill study.Ann Oncol 3: 301–305PubMedGoogle Scholar
  70. Fowler JE Jr (1987) Nephrectomy in metastatic renal cell carcinoma. Urol Clin North Am 14: 749–756PubMedGoogle Scholar
  71. Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 [Suppl 1): 555Google Scholar
  72. Frohmuller HG, Grups JW, Heller V (1987) Comparative value of ultrasonography, computerized tomography, angiography and excretory urography in the staging of renal cell carcinoma.) Urol 138: 482–484Google Scholar
  73. Fugitt RB,Wu GS, Martinelli LC (1973) An evaluation of postoperative radiotherapy in hypernephroma treatment–a clinical trial. Cancer 32: 1332–1340Google Scholar
  74. Galligioni E,Quaia M,Merlo A,Carbone A, Spada A, Favaro D et aí. (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin:five-year results of a prospective randomized study. Cancer 77: 2560–2566PubMedGoogle Scholar
  75. Gleave ME, Elhilali M, FradetY, Davis I,Venner P, Saad F et al. (1998) Interferon gamma-1 b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338: 12651271Google Scholar
  76. Glenn GM, Daniel LN, Choyke P, Linehan WM, Oldfield E, Gorin MB et al. (1991) Von Hippel-Lindau (VHL) disease:distinct phenotypes suggest more than one mutant allele at the VHL locus.Hum Genet 87: 207–210Google Scholar
  77. Gnarra JR,Glenn GM, Latif F,Anglard P, Lerman MI,Zbar B et aí. (1993) Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 20: 207–216PubMedGoogle Scholar
  78. Gnarra JR,Tory K,Weng Y, Schmidt L, Wei MH, Li H et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85–90PubMedGoogle Scholar
  79. Gnarra JR, Zhou S, Merill MJ et al. (1996) Posttranscriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci USA 93: 10589–10594PubMedGoogle Scholar
  80. Goldfarb DA, Novick AC, Lorig R,Bretan PN, Montie JE, PontesJE et al. (1990) Magnetic resonance imaging for assessment of vena caval tumor thrombi: a comparative study with venacavography and computerized tomography scanning. J Urol 144: 1100–1103; discussion 11031104Google Scholar
  81. Goldfarb DA (1998) Nephron-sparing surgery and renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. J Intern Med 243: 563–567PubMedGoogle Scholar
  82. Gottesman JE,Crawford ED, Grossman HB,Scardino P, McCracken JD (1985) Infarction-nephrectomy for metastatic renal carcinoma. Southwest oncology group study. Urology 25: 248–250Google Scholar
  83. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama 5, MacLennan G et al. (1997)TNM staging of renal cell carcinoma:Workgroup No.3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).Cancer 80: 992–993Google Scholar
  84. Gulanikar AC, Daily PP, Kilambi NK, Hamrick-Turner JE, Butkus DE (1998) Prospective pretranspiant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation 66: 1669–1672PubMedGoogle Scholar
  85. Henriksson R, Nilsson S,Colleen S, Wersall P, Helsing M,Zimmerman R et al. (1998) Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs. interleukin 2,alpha-interferon (leucocyte) and tamoxifen. BrJCancer77: 1311–1317Google Scholar
  86. Herman JG, Latif F,Weng Y et al. (1994) Silencing of theVHL tumor suppressor gene by DNA methylation in renal cell carcinoma. Proc. Natl Acad Sci USA 91: 9700–9704Google Scholar
  87. Herr HW (1994a) Partial nephrectomy for incidental renal cell carcinoma. Br J Urol 74: 431–433PubMedGoogle Scholar
  88. Herr HW (1994b) Partial nephrectomy for renal cell carcinoma with a normal opposite kidney.Cancer 73: 160–162Google Scholar
  89. Hoelzel D, Klamert A, Schmidt C (1996) Nierenkarzinom. In: Krebs: Häufigkeiten, Befunde, Behandlungsergebnisse. Zuckschwerdt, München Berlin Wien New York, S 399–409Google Scholar
  90. Hon WC,Wilson MI, Harlos K et al. (2002) Structural basis for the recognition of hydroxyproline in 1–11F-1 alpha by pVHL. Nature 417: 975–978PubMedGoogle Scholar
  91. Horan JJ, Robertson CN,Choyke PL, Frank JA, Miller DL, Pass HI et al. (1989) The detection of renal carcinoma extension into the renal vein and inferior vena cava: a prospective comparison of venacavography and magnetic resonance imaging. J Urol 142: 943–947; discussion 947948Google Scholar
  92. Hosoe S, Brauch H, Latif F, Glenn G, Daniel L, Bale S et al. (1990) Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 8: 634–640PubMedGoogle Scholar
  93. Hrushesky WJ, von Roemeling R, Fraley EE, Rabatin JT (1988) Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. Semin Surg Oncol 4: 110–115PubMedGoogle Scholar
  94. Hrushesky WI, von Roemeling R, Lanning RM, Rabatin JT (1990) Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.J Clin Oncol 8: 1504–1513Google Scholar
  95. Huland E, Heinzer H, Huland H,Yung R (2000) Overview of interleukin-2 inhalation therapy.Cancer J Sci Am 6 [Suppl 1]: 5104–5112Google Scholar
  96. Iliopolous O, Jiang C, Levy AP (1996) Negative regulation of hypoxiy inducible genes by the von Hippel Lindau Protein. Proc Natl Acad Sci USA 93: 10595–10599Google Scholar
  97. Iliopolous O, Ohh M, Kaelin W (1998) pVHL 19 is a biologically active product of the von Hippel Lindau gene arising from an internal translation initiation. Proc Natl Acad Sci USA 95: 11661–11666Google Scholar
  98. Iliopoulos 0, Eng C (2000) Genetic and Clinical aspects of familial renal neoplasms. Seminars in Oncolog 27: 138–149Google Scholar
  99. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648–657PubMedGoogle Scholar
  100. Inoue K, Karashima T,Chikazawa M, liyamaT,Yoshikawa C, Furihata M et al. (1998) Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth. Virchows Arch 433: 511–515PubMedGoogle Scholar
  101. lqbal MA,Akhtar M, Ali MA (1996) Cytogenetic findings in renal cell carcinoma. Hum Pathol 27: 949–954Google Scholar
  102. Ishikawa I, Saito Y, Shikura N, Kitada H, Shinoda A, Suzuki S (1990) Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 16: 452–458PubMedGoogle Scholar
  103. Ishikawa I (1993) Renal cell carcinoma in chronic hemodialysis patients–a 1990 questionnaire study in Japan. Kidney Int Suppl 41: 51679: 9167–9Google Scholar
  104. Janosko ED, Powell CS, Spence PA, Hodges WE, Lust RM (1991) Surgical management of renal cell carcinoma with extensive intracaval involvement using a venous bypass system suitable for rapid conversion to total cardiopulmonary bypass.) Urol 145: 555–557Google Scholar
  105. Johnson CD, Dunnick NR,Cohan RH, Illescas FF (1987) Renal adenocarcinoma: CT staging of 100 tumors. Am J Roentgenol 148: 59–63Google Scholar
  106. Jones PA (1999) Cancer epigenetics come of age. Nat Genet 21: 163–167PubMedGoogle Scholar
  107. Juul N,Torp-Pedersen S, Gronvall S, Holm HH, Koch F, Larsen S (1985) Ultrasonically guided fine needle aspiration biopsy of renal masses.) Urol 133: 579–581Google Scholar
  108. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC (2000) Activation of HIF1 alpha ubiquitylation by a reconstituted von Hippel Lindau tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430–10435PubMedGoogle Scholar
  109. Kao PC, Klee GG,Taylor RL, Heath H 3rd (1990) Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions (see comments). Mayo Clin Proc 65: 1399–1407Google Scholar
  110. Kardar AN, Arafa M, Al Suhaibani H, Pettersson BA, Lindstedt E, Hanash KA et al. (1998) Feasibility of adrenalectomy with radical nephrectomy. Urology 52: 35–37PubMedGoogle Scholar
  111. Karstaedt N, McCullough DL, Wolfman NT, Dyer RB (1986) Magnetic resonance imaging of the renal mass.) Urol 136: 566–570Google Scholar
  112. Katz DL,Zheng T, Holford TR, Flannery J (1994)Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935–1989. Int J Cancer 58: 57–63Google Scholar
  113. Kibel A, Iliopoulos 0, DeCaprio JA, Kaelin WG, Jr (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269: 1444–1446PubMedGoogle Scholar
  114. Kim WJ, Kakehi Y, Kinoshita H,Arao S,Fukumoto M,Yoshida 0 (1996) Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney.J Urol 156: 506–511Google Scholar
  115. Kjaer M, Iversen P, Hvidt V, Bruun E, Skaarup P, Bech Hansen Jet al. (1987) A randomized trial of postoperative radiotherapy versus observation in stage II and Ill renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group.Scand J Urol Nephrol 21: 285–289Google Scholar
  116. Kovacs A, Kovacs G (1992) Low chromosome numbers in chromophobe renal cell carcinomas. Genes Chromosome Cancer 4: 267–268Google Scholar
  117. Kovacs G, Brusa P (1989) Clonal chromosome aberrations in normal kidney tissue from patients with renal cell carcinoma (letter). Cancer Genet Cytogenet 37: 289–290PubMedGoogle Scholar
  118. Kriegmair M, Oberneder R, Hofstetter A (1995) Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45: 758–762PubMedGoogle Scholar
  119. Kuebler JP, Hogan TF,Trump DL, Bryan GT (1984) Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma.CancerTreat Rep 68: 925–926Google Scholar
  120. Kugler A, Stuhler G, Walden Petal. (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Medicine 6: 332–336PubMedGoogle Scholar
  121. Kurth KH, Debruyne FM, Hall RR, Denis L,Verbaes A, Bollack C et al. (1987) Embolization and postinfarction nephrectomy in patients with primary metastatic renal adenocarcinoma. Eur Urol 13: 251–255PubMedGoogle Scholar
  122. La Vecchia C, Negri E, D’Avanzo B, Franceschi S (1990) Smoking and renal cell carcinoma. Cancer Res 50: 5231–5233PubMedGoogle Scholar
  123. Lamiell JM, Salazar FG, Hsia YE (1989) von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 68: 1–29Google Scholar
  124. Lang EK (1984) Comparison of dynamic and conventional computed tomography, angiography, and ultrasonography in the staging of renal cell carcinoma. Cancer 54: 2205–2214PubMedGoogle Scholar
  125. Latif F,Tory K,Gnarra J,Yao M, Duh FM, Orcutt ML et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317–1320PubMedGoogle Scholar
  126. Law TM, Ilson DH, Motzer RJ (1994) Phase!! trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 12: 143–145PubMedGoogle Scholar
  127. Leibovitch I, Raviv G, MorY, Nativ O,Goldwasser B (1995) Reconsidering the necessity of ipsilateral adrenalectomy during radical nephrectomy for renal cell carcinoma. Urology 46: 316–320Google Scholar
  128. Levinson AK, Johnson DE, Strong LC, Pathak S, Huff V, Saunders GF (1990) Familial renal cell carcinoma: hereditary or coincidental? J Urol 144: 849–851PubMedGoogle Scholar
  129. Levy DA, Slaton JW, Swanson DA, Dinney CP (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma.) Urol 159: 1163–1167Google Scholar
  130. Li FP, Decker HJ,Zbar B et al. (1993) Clinical and genetic studies of renal cell carcinomas in a family with constitutional chromosome 3;8 translocation.Ann Int Med 118: 106–111Google Scholar
  131. Licht MR, Novick AC, Goormastic M (1994) Nephron sparing surgery in in- cidental versus suspected renal cell carcinoma.) Urol 152: 39–42Google Scholar
  132. Lindblad P, Chow WH, Chan J, Bergstrom A, Wolk A, Gridley G et al. (1999) The role of diabetes mellitus in the aetiology of renal cell cancer ( In Process Citation ). Diabetologia 42: 107–112Google Scholar
  133. Lindblad P, Wolk A, Bergstrom R, Persson I, Adami HO (1994) The role of obesity and weight fluctuations in the etiology of renal cell cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 3: 631–639PubMedGoogle Scholar
  134. Linehan WM, Lerman MI,Zbar B (1995) Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273: 564–570Google Scholar
  135. Lisztwan J, Imbert G,Wirbelauer C, Gsteiger M, Krek W (1999) The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiqui-tin protein Ligase activity. Genes Dev 13: 1822–1833Google Scholar
  136. Ljungberg B,Alamdari FI, Holmberg G,Granfors T,Duchek M (1998) Radical nephrectomy is still preferable in the treatment of localized renal cell carcinoma.A long-term follow-up study. Eur Urol 33: 79–85PubMedGoogle Scholar
  137. Lorenz J,Wilhelm K, Kessler M et al. (1996) Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 2: 1115–1122PubMedGoogle Scholar
  138. Los M, Jansen GH, Kaelin WG, Lips Cl, Blijham GH, Voest EE (1996) Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 75: 231–238PubMedGoogle Scholar
  139. Maldazys JD,deKernion JB (1986) Prognostic factors in metastatic renal carcinoma.) Urol 136: 376–379Google Scholar
  140. Mandel IS, McLaughlin JK, Schlehofer B, Mellemgaard A, Helmert U, Lindblad Petal. (1995) International renal-cell cancer study. IV. Occupation. Intl Cancer 61: 601–605Google Scholar
  141. Manski Ti, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D et al. (1997) Endolymphatic sac tumors.A source of morbid hearing loss in von Hippel- Lindau disease.JAMA 277: 1461–1466Google Scholar
  142. Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM et al. (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.J Urol 150: 463–466Google Scholar
  143. Marincola FM, White DE, Wise AP, Rosenberg SA (1995) Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.J Clin Oncol 13: 1110–1122Google Scholar
  144. Marshall FF, Steinberg GD, Pound CR, Partin AW (1995) Radical surgery for renal-cell carcinoma: cavai neoplastic excision, adrenalectomy, lymphadenectomy, adjacent organ resection. World J Urol 13: 159162Google Scholar
  145. Maxwell PH, Wiesener MS, Chang GW et al. (1999) The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 399: 271–275PubMedGoogle Scholar
  146. McCredie M, Stewart JH, Day NE (1993) Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 53: 245–249PubMedGoogle Scholar
  147. McCredie M, Pommer W, McLaughlin JK, Stewart JH, Lindblad P, Mandel JS et al. (1995) International renal-cell cancer study. 11. Analgesics. Int J Cancer 60: 345–349Google Scholar
  148. McLaughlin JK, Lindblad P, Mellemgaard A, McCredie M, Mandel JS, Schlehofer Bet al. (1995) International renal-cell cancer study.I.Tobacco use. Int i Cancer 60: 194–198Google Scholar
  149. Mellemgaard A, Engholm G, McLaughlin JK, Olsen JH (1994a) Occupational risk factors for renal-cell carcinoma in Denmark. Scand J Work Environ Health 20: 160–165PubMedGoogle Scholar
  150. Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLaughlin JK, Olsen JH (1994b) Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 23: 923–930PubMedGoogle Scholar
  151. Mellemgaard A, Lindblad P, Schlehofer B, Bergstrom R, Mandel JS,McCredie M et al. (1995) International renal-cell cancer study.III. Role of weight, height, physical activity, and use of amphetamines. Int J Cancer 60: 350–354Google Scholar
  152. Mickisch GH, Noordzij MA, v.d.Gaast A, Gebreamlack P, Kohrmann KU, Mogler-Drautz E et al.(1995) Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.) Cancer Res Clin Oncol 121 Suppl 3: R11–6: R11–6Google Scholar
  153. Mickisch GH, Garin A, van Poppel H et al. (2001) Radical nephrectomy plus interferon a compared with interferon a alone in metastatic renal cell carcinoma. Lancet 358: 966PubMedGoogle Scholar
  154. Mihara S, Nagano K, Kuroda K,Yoshioka R, Sawatari M, Koba H et al. (1998) Efficacy of ultrasonic mass survey for abdominal cancer.) Med Syst 22: 55–62Google Scholar
  155. Minasian LM,Motzer Ri,Gluck L,Mazumdar M,VlamisV, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.J Clin Oncol 11: 1368–1375Google Scholar
  156. Mizuno N,Naruse S,Kitagawa M, Ishiguro H, NakaeY, leda H et al. (1998) Islet cell tumor in von Hippel-Lindau disease. Intern Med 37: 295–299PubMedGoogle Scholar
  157. Moll V, Becht E, Ziegler M (1993) Kidney preserving surgery in renal cell tumors: indications, techniques and results in 152 patients. J Urol 150: 319–323PubMedGoogle Scholar
  158. Morgan WR, Zincke H (1990) Progression and survival after renal-conserving surgery for renal cell carcinoma:experience in 104 patients and extended follow-up. J Urol 144:852–857; discussion 857–858Google Scholar
  159. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C et al. (1995) Phase I/11 trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.) Clin Oncol 13: 1958–1965Google Scholar
  160. Motzer RJ, Bacik J, Murphy BA et al. (2002) Interferon alfa as comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.) Clin Oncol 20: 289Google Scholar
  161. Negrier S, Escudier B, Douillard JY, Lesimple T, Rossi JF, Viens Petal. (1996) Randomized study of interleukin 2 and interferon with or without 5-FU in metastatic renal cell cancer. Proc ASCO 16: 326a [Abstract]Google Scholar
  162. Negrier S, Escudier B, Lasset C,Douillard JY,SavaryJ,Chevreau C et a1. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Eng1 J Med 338: 1272–1278PubMedGoogle Scholar
  163. Neidhart JA, Anderson SA, Harris JE, Rinehart JJ, Laszlo J, Dexeus FH et al. (1991) Vinblastine fails to improve response of renal cancer to interferon alfa-nl: high response rate in patients with pulmonary metastases. J Clin Oncol 9: 832–836PubMedGoogle Scholar
  164. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ et al. (1993) Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease.N Engl J Med 329: 1531–1538Google Scholar
  165. Novick AC, Streem SB (1992) Long-term follow-up after nephron sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. J Urol 147: 1488–1490PubMedGoogle Scholar
  166. Novick AC (1998) Nephron-sparing surgery for renal cell carcinoma. Br J Urol 82: 321–324PubMedGoogle Scholar
  167. Osborne JP, Fryer A,Webb D (1991) Epidemiology of tuberous sclerosis.Ann NY Acad Sci 615: 125–127Google Scholar
  168. Partanen T, Heikkila P, Hernberg S,Kauppinen T, Moneta G,Ojajarvi A (1991) Renal cell cancer and occupational exposure to chemical agents. Scand J Work Environ Health 17: 231–239Google Scholar
  169. Pathak S, Goodacre A (1986) Specific chromosome anomalies and predisposition to human breast, renal cell, and colorectal carcinoma. Cancer Genet Cytogenet 19: 29–36PubMedGoogle Scholar
  170. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM et al. (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94: 2156–2161PubMedGoogle Scholar
  171. Perez Ordonez P, Hamed G, Campbell S et al. (1997) Renal oncocytoma. A clinicopathological study of 70 cases. Am J Surg Pathol 21: 871–883Google Scholar
  172. Phillips E, Messing EM (1993) Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology 41: 9–15PubMedGoogle Scholar
  173. Pizzocaro G, Piva L, Di Fronzo G, Giongo A, Cozzoli A, Dormia E et al. (1987) Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer:5-year results of a prospective randomized study.J Urol 138: 1379–1381Google Scholar
  174. Pizzocaro G, Piva L, Costa A, Silvestrini R (1997) Adjuvant Interferon to radical nephrectomy in Robsons stages Il and Ill renal cell cancer,a multicenter randomized study with some biological evaluations.ASCO Proceedings 1132a [Abstract]Google Scholar
  175. Polacsik T.1, Cairns P, Epstein JL et al. (1996) Distal nephron tumors: Microsatellite allelotype.Cancer Res 56: 1892–1895Google Scholar
  176. Porena M,Vespasiani G, Rosi P, Costantini E,Virgili G, Mearini E et al. (1992) Incidentally detected renal cell carcinoma: role of ultrasonography. J Clin Ultrasound 20:395–400Google Scholar
  177. Poston CD, Jaffe GS, Lubensky IA, Solomon D, Zbar B, Linehan WM et al. (1995) Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease:clinical and molecular genetic implications.) Urol 153: 22–26Google Scholar
  178. Presti JC Jr, Rao PH,Chen Q, Reuter VE, Li FP, Fair WR et al. (1991) Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res 51: 1544–1552PubMedGoogle Scholar
  179. Prowse A, Webster A, Richards F et aí. (1997) Somativ inactivation of the VHL gene in Von Hippel Lindau disease tumors. Am J Human Genetics 60: 765–771Google Scholar
  180. Prummer O (1993) Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial.The Delta-P Study Group. Cancer 71: 1828–1834PubMedGoogle Scholar
  181. Pyrhänen S, Salmin G, Lektonen T, Nurmi M,Tamela T, Runtu M et al. (1996) Recombinant interferon alpha 2a with vinblastine vs.vinblastin alone in advanced renal cell carcinoma:A phase III study.Proc ASCO 15: 614a [Abstract]Google Scholar
  182. Quesada JR, Swanson DA, Gutterman JU (1985) Phase II study of interferon alpha in metastatic renal-cell carcinoma:a progress report.) Clin On-col 3: 1086–1092Google Scholar
  183. Rackley R, Novick A, Klein E,Bukowski R, McLain D,Goldfarb D (1994)The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma.J Urol 152: 1399–1403Google Scholar
  184. Ramdave S,Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HAT et al. (2001) Clinical role of F 18-fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166: 825–830PubMedGoogle Scholar
  185. Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C et al. (1998) Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma:a multicenter phase II trial.Groupe Francais d’Immunotherapie.J Clin Oncol 16: 2728–2732Google Scholar
  186. Repmann R, Wagner S, Richter A (1997) Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy ( ASI) using autologous tumor vaccine. Anticancer Res 17: 2879–2882Google Scholar
  187. Reuter VE, Presti JC (2000) Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 27: 124–137PubMedGoogle Scholar
  188. Richard S, Beigelman C, Duclos JM, Fendler JP, Plauchu H, Plouin PF et al. (1994) Pheochromocytoma as the first manifestation of von HippelLindau disease.Surgery 116: 1076–1081Google Scholar
  189. Richards FM,Crossey PA, Phipps ME, Foster K, Latif F, Evans G et al. (1994) Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet 3: 595–598PubMedGoogle Scholar
  190. Richards FM, Phipps ME, Latif F,Yao M,Crossey PA, Foster K et al. (1993) Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. Hum Mol Genet 2: 879–882PubMedGoogle Scholar
  191. Ritchie AW,deKernion JB (1987) The natural history and clinical features of renal carcinoma. Semin Nephrol 7: 131–139PubMedGoogle Scholar
  192. Roach ES, Gomez Gomez MR, Northrup H (1998) Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria.J Child Neurol13:624–628Google Scholar
  193. Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Berman A et al. (1990) Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.) Urol 144:614–617; discussion 617–618Google Scholar
  194. Robson CJ, Churchill BM,Anderson W (1969)The results of radical nephrectomy for renal cell carcinoma.J Urol 101:297–301Google Scholar
  195. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA (1991) Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 180: 85–89PubMedGoogle Scholar
  196. Samaan NA (1978) Paraneoplastic syndromes associated with renal carcinoma. In: Clinical conference on cancer, 23d. MD Anderson Hospital and Tumor Institute, Houston, pp 73–78Google Scholar
  197. Sampson JR (1996) The kidney in tuberous sclerosis: manifestations and molecular mechanisms. Nephrol Dial Transplant 11: 34–37PubMedGoogle Scholar
  198. Sampson JR, Maheshvar MM, Aspinwall R et al. (1997) Renal cystic disease in tuberous sclerosis: Role of the polycystic kidney disease gene 1. Am J Hum Genet 61: 843–841PubMedGoogle Scholar
  199. Samuels BL, Hollis DR, Rosner GL,Trump DL, Shapiro CL,Vogelzang NJ et al. (1997) Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.Clin Cancer Res 3: 1977–1984PubMedGoogle Scholar
  200. Sandock DS,Seftel AD, Resnick MI (1997) Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology 49: 28–31PubMedGoogle Scholar
  201. Sawczuk IS, Graham SD,Miesowicz F (1997) Randomized controlled trial of adjuvant therapy with ex vivo activated T cells in T1–3 orT4N+M0 renal cell carcinoma. ASCO Proceedings 16: 1163a [Abstract]Google Scholar
  202. Schlehofer B, Heuer C, Blettner M, Niehoff D, Wahrendorfi (1995) Occupation, smoking and demographic factors, and renal cell carcinoma in Germany.lnt J Epidemiol 24: 51–57Google Scholar
  203. Schlehofer B, Pommer W, Mellemgaard A, Stewart JH, McCredie M, Niwa S et al. (1996) International renal-cell-cancer study.Vl. the role of medical and family history.lnt J Cancer 66: 723–726Google Scholar
  204. Schmidt D, Neumann HP (1995) Retinal vascular hamartoma in von HippelLindau disease. Arch Ophthalmol 113: 1163–1167PubMedGoogle Scholar
  205. Schmidt L, Duh FM, Chen F (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal cell carcinomas. Nature Genetics 16: 68–73PubMedGoogle Scholar
  206. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68–73PubMedGoogle Scholar
  207. Schmidt L, Junker K, Weirich G et al. (1998) Two North American families with hereditary papillary renal cell carcinoma and identical mutations in the MET Oncogene. Cancer Res 58: 1719–1722PubMedGoogle Scholar
  208. Schoenfeld A, Davidowitz EJ, Burk RD (1998) A second major native von Hippel Lindau gene product initiated from an internal translation start site functions as a tumor suppressor. Proc Natl Acad Sci USA 95: 8817–8822PubMedGoogle Scholar
  209. Schomburg A, Kirchner H, Fenner M, Menzel T, Poliwoda H, Atzpodien J (1993) Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. Eur1 Cancer 29A: 737–740Google Scholar
  210. Schwerdtle RF, Storkel S, Neuhaus C, Brauch H, Weidt E, Brenner W et al. (1996) Allelic losses at chromosomes 1 p, 2p, 6p,10p,13q,17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma.Cancer Res 56: 2927–2930Google Scholar
  211. Seizinger BR, Rouleau GA, Ozelius U, Lane AH, Farmer GE, Lamiell JM et al. (1988) Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268–269PubMedGoogle Scholar
  212. Semelka RC, Shoenut JP, Magro CM, Kroeker MA, MacMahon R, Greenberg HM (1993) Renal cancer staging:comparison of contrast-enhanced CT and gadolinium- enhanced fat-suppressed spin-echo and gradient-echo MR imaging.J Magn Reson Imaging 3: 597–602Google Scholar
  213. Semenza GL (2001) HIF-1,O(2),and the 3 PHDs: how animal cells signal hypoxia to the nucleus.Cell 107: 1–3Google Scholar
  214. Silverberg SG, Evans RH, Koehler AL (1969) Clinical and pathologic features of initial metastatic presentations of renal cell carcinoma. Cancer 23: 1126–1132PubMedGoogle Scholar
  215. SinikZ,AlkibayT,Ataoglu O,Biri H,Sozen S, Deniz N et al. (1997) Nuclear p53 overexpression in bladder, prostate, and renal carcinomas. IntJ Urol 4: 546–551Google Scholar
  216. Stadler WM, Kuzel T, Dumas M,Vogelzang NJ (1998) Multicenter phase Il trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 16: 1820 1825Google Scholar
  217. Stahl M, Wilke H, Schmoll Hi, Schober C, Diedrich H, Casper J et al. (1992) A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 3: 167–168PubMedGoogle Scholar
  218. Steinbach F, Stockle M, Hohenfellner R (1995) Clinical experience with nephron-sparing surgery in the presence of a normal contralateral kidney. Semin Urol Oncol 13: 288–291PubMedGoogle Scholar
  219. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG et al. (1997) Classification of renal cell carcinoma:Workgroup No.1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).Cancer 80: 987–989PubMedGoogle Scholar
  220. Storkel S, van den Berg E (1995) Morphological classification of renal cancer. World J Urol 13: 153–158PubMedGoogle Scholar
  221. Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D et al. (1990) Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases.) Urol 144: 243–245Google Scholar
  222. Tammela TL, Leinonen AS, Kontturi MJ (1991) Comparison of excretory urography,angiography, ultrasound and computed tomography forT category staging of renal cell carcinoma. Scand J Urol Nephrol 25: 283–286PubMedGoogle Scholar
  223. Tannenbaum M (1971) Ultrastructural pathology of human renal cell tumors. Pathol Annu 6: 249–277PubMedGoogle Scholar
  224. Tavani A, La Vecchia C (1997) Epidemiology of renal-cell carcinoma. J Nephrol 10: 93–106PubMedGoogle Scholar
  225. Thoenes W, Storkel S, Rumpelt HJ, Moll R, Baum HP, Werner 5 (1988) Chromophobe cell renal carcinoma and its variants–a report on 32 cases. J Pathol 155: 277–287Google Scholar
  226. Thoenes W, Storkel S,Rumpelt Hi (1986) Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181: 125–143Google Scholar
  227. Thompson IM, Peek M (1988) Improvement in survival of patients with renal cell carcinoma–the role of the serendipitously detected tumor. J Urol 140: 487–490PubMedGoogle Scholar
  228. Thrasher JB, Clark JR, Cleland BP (1990) Surgery for pulmonary metastases from renal cell carcinoma. Army experience from 1977–1987. Urology 35: 487–491PubMedGoogle Scholar
  229. Thrasher JB, Robertson JE, Paulson DF (1994) Expanding indications for conservative renal surgery in renal cell carcinoma. Urology 43: 160168Google Scholar
  230. Tobe SW, Noble-Topham SE,Andrulis IL, Hartwick RW,Skorecki KL,Warner E (1995) Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage.Clin Cancer Res 1: 1611–1615Google Scholar
  231. Tory K, Brauch H, Linehan M, Barba D, Oldfield E, Filling-Katz M et al. (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease.J Nati Cancer Inst 81: 1097–1101Google Scholar
  232. Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A et al. (1998) Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.J Clin Oncol 16: 2505–2513Google Scholar
  233. Treiger BF, Humphrey LS, Peterson CV Jr, Oesterling JE, Mostwin JL, Reitz BA et al. (1991) Transesophageal echocardiography in renal cell carcinoma: an accurate diagnostic technique for intracaval neoplastic extension.J Urol 145: 1138–1140Google Scholar
  234. Ueda T, Nishitani H, Kudo H (1988) Comparison of angiography and computed tomography using new morphologic criteria in staging of renal cell carcinoma. Urology 32: 459–464PubMedGoogle Scholar
  235. Utz DC,Warren MM, Gregg JA, Ludwig J, Kelalis PP (1970) Reversible hepatic dysfunction associated with hypernephroma. Mayo Clin Proc 45: 161–169PubMedGoogle Scholar
  236. Vamvakas S, Bruning T,Thomasson B, Lammert M, Baumuller A, Bolt HM et al. (1998) Renal cell cancer correlated with occupational exposure to trichloroethene.J Cancer Res Clin Oncol 124: 374–382Google Scholar
  237. Vogelzang NJ, Stadler WM (1998) Kidney cancer. Lancet 352:1691–1696 Vogelzang NJ, Yang X, Goldman S,Vijayakumar S, Steinberg G (1998) Radiation induced renal cell cancer: a report of 4 cases and review of the literature.J Urol 160: 1987–1990Google Scholar
  238. Walther M, Choyke P, Weiss G (1995) Parenchymal sparing surgery in pa- tients with hereditary renal cell carcinoma.J Urol 153: 913–916Google Scholar
  239. Walther MM, Lubensky IA,Venzon D,Zbar B, Linehan WM (1995) Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications.J Urol 154: 2010–2014; discussion 2014–2015Google Scholar
  240. Walther MM, Patel B,Choyke PL,Lubensky IA,Vocke CD, Harris C et a1. (1997) Hypercalcemia in patients with metastatic renal cell carcinoma:effect of nephrectomy and metabolic evaluation.J Urol 158: 733–739Google Scholar
  241. Walther MM,Yang JC, Pass HI, Linehan WM, Rosenberg SA (1997) Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma.J Urol 158: 1675–1678Google Scholar
  242. Warshauer DM, McCarthy SM, Street L, Bookbinder MJ, Glickman MG, Richter) et a1. (1988) Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology 169: 363–365Google Scholar
  243. Washecka R, Hanna M (1991) Malignant renal tumors in tuberous sclerosis. Urology 37: 340–343PubMedGoogle Scholar
  244. Webster AR, Richards FM, MacRonald FE, Moore AT, Maher ER (1998) An analysis of phenotypic variations in the familial cancer syndrome von Hippel Lindau disease: Evidence for modifier effects. Am J Hum Genet 63: 1025–1035Google Scholar
  245. Weirich G, Glenn G,Junker K et al. (1998) Familial renal oncocytome: clinicopathological study of 5 families.J Urol 160: 335–340Google Scholar
  246. Weterman MA, Wilbrink M, Van Kessel AG (1996) Fusion of the transcription factor TFE3 to a novel gene PRCC ind t(X;a)(p11;g21) positive papillary renal cell carcinomas. Proc Natl Acad Sci Usa 93: 1529415298Google Scholar
  247. Wienecke R, Koning A, De Clue J (1995) Identification of tuberin, the tuberous sclerosis gene 2 product.Tuberin possesses specific Rap1GAP activity.J Biol Chem 270: 16409–16414Google Scholar
  248. Wilkinson MJ, Frye JW,Small EJ,Venook AP,Carroll PR, Ernest ML et al. (1993) A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer 71: 3601–3604PubMedGoogle Scholar
  249. Wing GL,WeiterJJ,Kelly PJ,Albert DM,GonderJR (1981) von Hippel-Lindau disease: angiomatosis of the retina and central nervous system. Ophthalmology 88:1311–1314Google Scholar
  250. Winter P, Miersch WD,Vogel J, Jaeger N (1990) On the necessity of adrenal extirpation combined with radical nephrectomy.J Urol 144:842–843; discussion 844Google Scholar
  251. Wunderlich H, Schumann S, Jantitzky V, Moravek P, Podhola M, Kosmehl H et al. (1998) Increase of renal cell carcinoma incidence in central Europe. Eur Urol 33: 538–541PubMedGoogle Scholar
  252. Xiao GH, Shoarinejad F, Jin F et al. (1997) The tuberous sclerosis gene 2 product tuberin functions as a RabS GTPase activating (GAP) protein in modulating endocytosis.J Biol Chem 272: 6097–6100Google Scholar
  253. Yagoda A,Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma:1983–1993. Semin Oncol 22: 42–60PubMedGoogle Scholar
  254. Yamashita Y, Honda S, Nishiharu T, Urata J,Takahashi M (1996) Detection of pseudocapsule of renal cell carcinoma with MR imaging and CT.Am J Roentgenol 166: 1151–1155Google Scholar
  255. Yang JC, Rosenberg SA (1997) An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.CancerJ Sci Am 3 [Suppl 1]: 579–584Google Scholar
  256. Yao M, Latif F, Orcutt ML, Kuzmin I, StackhouseT, Zhou FW et al. (1993) von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis. Hum Genet 92: 605–614Google Scholar
  257. Yao M, Shuin T (1995) Familial renal cell carcinoma: review of recent molecular genetics. Int J Urol 2: 61–70PubMedGoogle Scholar
  258. Yeung RS, Xiao GH, Jin F et al. (1994) Predisposition to renal cell carcinoma in the EKER rat is determined by germ line mutation of the tuberous sclerosis 2 gene. Proc. Nati Acad Sci USA 91: 11413–11416Google Scholar
  259. Young J, Povey S (1998) The genetic basis of tuberous sclerosis. Mol Med 4: 313–319Google Scholar
  260. Yu DS,Chang SY, Ma CP (1998) The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol 82: 544–547PubMedGoogle Scholar
  261. Yu MC, MackTM,Hanisch R,Cicioni C, Henderson BE (1986) Cigarette smoking, obesity, diuretic use,and coffee consumption as risk factors for renal cell carcinoma.J Natl Cancer Inst 77: 351–356Google Scholar
  262. Zabbo A, Novick AC, Risius B, Montie JE (1985) Digital subtraction angiography for evaluating patients with renal carcinoma.J Urol 134: 25 2255Google Scholar
  263. Zbar B,Tory K, Merino M, Schmidt L, Glenn G, Choyke Petal. (1994) Hereditary papillary renal cell carcinoma.J Urol 151: 561–566Google Scholar
  264. Zbar B, Glenn G, Lubensky I, Choyke P, Walther MM, Magnusson G et al. (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families.J Urol 153: 907–912Google Scholar
  265. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM et al. (1996) Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8: 348357Google Scholar
  266. Zeiger MA,Zbar B, Keiser H, Linehan WM,Gnarra JR (1995) Loss of heterozygosity on the short arm of chromosome 3 in sporadic,von Hippel-Lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes Cancer 13: 151–156PubMedGoogle Scholar
  267. Zhang XH,Takenaka I,Sato C,Sakamoto H (1997) p53 and HER-2 alterations in renal cell carcinoma. Urology 50:636–642Google Scholar
  268. Zincke H, Swanson SK (1982) Bilateral renal cell carcinoma: influence of synchronous and asynchronous occurrence on patient survival.J Urol 128: 913–915Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • W. E. Aulitzky
  • J. Beck
  • C. Huber

There are no affiliations available

Personalised recommendations